Post by Genentech

Name: The FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review f
Uploaded: 2026-06-11T13:00:15.853Z
Channel: Genentech
Description: The FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in stage III deficient Mismatch Repair (dMMR) or

943,442 followers

The FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in stage III deficient Mismatch Repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer. Colon cancer remains a major global health challenge, with one in three patients with stage III disease relapsing within five years. Learn more about the potential impact of this immunotherapy combination: http://spr.ly/6045B84QLf

Video Content